Privately-held Swedish firm Salipro Biotech has entered into a research collaboration with Japan's Sumitomo Pharma (TYO: 4506) to reveal the mechanism of action and pharmacological characterization of a drug candidate.
Under the terms of the collaboration, Salipro will use its expertise in stabilizing challenging membrane proteins such as GPCRs, ion channels and transporters via its proprietary technology platform, to advance a Sumitomo Pharma’s drug discovery program by characterizing a drug candidate with the desired therapeutic properties against a selected target.
Previously, Salipro has signed multiple research collaborations with a number of top-tier pharma and biotech companies including AstraZeneca (LSE: AZN) and Sanofi (Euronext: SAN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze